Track the 메타바이오메드 share price and the full management transaction log of the company, a listed issuer based in South Korea. Shares trade on KR KR, under the supervision of DART (FSS). Operating in the Health Care sector, 메타바이오메드 has logged 36 reports. Market capitalisation: €102.3bn. The latest transaction was reported on 16 July 2026 (Purchase). Among the most active insiders: 오지수. The full history is openly available.
36
Insider Decl.
n/a
Thresholds
€1,687
27 ops.
Buy Volume
n/a
1 ops.
Sell Volume
22Σ signal
Buys €1,687n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 6,301 of 28,169 companies
65.4
score / 100
Value
67
Quality
64
FCF yld-0.6%
Earn yld10%
EV/EBITDA7.2x
ROE·
Gross mgn52%
Net mgn11%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Meta Biomed is a company listed on the XKRX market, specializing in the healthcare and pharmaceutical sector. It focuses on the development and commercialization of innovative solutions for the medical field.